Navigation Links
ATUM Launches Cell-Line Development Service
Date:4/10/2017

NEWARK, Calif., April 10, 2017 /PRNewswire/ -- ATUM (formerly DNA2.0) has announced an expansion of its services to include cell line development, which has been enabled by the company's proprietary Leap-In Transposase genome engineering tools.  ATUM has also begun construction of a new, 7,000 SF mammalian cell engineering laboratory at its Newark, CA headquarters.  The new facility, slated to be fully operational by September 2017, will double ATUM's lab space dedicated to mammalian work, and will include a cGMP cell bank manufacturing facility that is expected to be fully validated by the end of the year.

"The Leap-In Transposases give us stable, highly productive cell lines in very short timeframes," said Ferenc Boldog, Ph.D., director of cell line development at ATUM and former head of cell line development at Shire. "In the era of CRISPR/Cas9 and TALENs, making gene knock-outs has been simplified. Leap-In Transposase complements these tools by enabling us to rapidly insert DNA of unlimited size into a target genome. The availability of two independent transposons allows us to make sequential genome modifications. For example, we can add half a dozen genes to modify glycosylation pathways using one transposase, then integrate 4 new genes to produce a bispecific antibody with an improved glycosylation profile."

ATUM has so far been granted four patents by the U.S. Patent and Trademark Office (USPTO) for the company's novel Leap-In Transposase technology:  "Enhanced nucleic acid constructs for eukaryotic gene expression," Patent Nos: 9,428,767; 9,574,209; 9,580,697 and 9,534,234.

"With Dr. Boldog's leadership, we have turned Leap-In from a research tool into a cell line development powerhouse," said Jeremy Minshull, CEO of ATUM.  "We are finding that this novel technology significantly accelerates stable pool and cell-line generation for protein pharmaceutical production.  We obtain high productivities when used in conjunction with metabolic selections such as dihydrofolate reductase (DHFR) and glutamine synthetase (GS) or more generic drug selections such as puromycin. Now that high yield stable pools are so quick and easy to make, our partners can move into their final production host earlier in the drug development process, thereby giving them added confidence about the properties of their molecules."

About the Leap-In Transposase® Technology
ATUM has discovered, characterized and patented two new families of transposases.  These have been engineered using ATUM's ProteinGPS technology for complex genome engineering of mammalian cells, including the rapid generation of high titer protein expression lines. The technology enables any recombinant DNA sequence to behave as a transposon -- a mobile genetic element -- and to efficiently transpose the cargo from delivery vectors to target cell chromosomes via a "cut & paste" mechanism. The Leap-In Transposase® rapidly catalyzes the stable, quasi-random integration of many copies of a transposon into the target genome. In contrast to more traditional "random integration" methods where the introduced DNA may be randomly fragmented and sequences lost, transposases integrate the entire transposon every time.  Transposons thus produce more stable and higher producing lines, and greatly reduce the downstream screening burden.

About ATUM
ATUM, formerly DNA2.0, offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering and production. ATUM exploits the dependence of biological activity on well-designed sequences. ATUM's tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. By collaborating with clients, ATUM accelerates breakthroughs and moves research further faster. The company is privately held and is headquartered in Newark, California. For more information, please visit https://www.atum.bio.

Contact:
Lisa Lilienthal, 404.661.3679
lisa@iconatl.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atum-launches-cell-line-development-service-300437198.html


'/>"/>
SOURCE ATUM
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Darrow Wealth Management Launches New Website
2. Guidepoint Global Launches Two Major Enhancements to its Client Research Portal
3. Elsevier Launches PracticeUpdate, a Free Information Portal for Physicians
4. Neogen launches rapid tests for ractopamine
5. Rockingham County Economic Development Launches New Website
6. BioHealth Innovation, Inc. Launches Program to Help Life Science Companies Navigate Federal Funding Application Process
7. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
8. Dr. Richard Charmoy Launches Groundbreaking Cavity Prevention Program that Can Lower Tooth Decay Rates by 74%
9. CellHealth Institute Launches with Support from Influential Investors
10. Dr. Timothy Rauch of Albuquerque, New Mexico Launches a Groundbreaking Cavity Prevention Program
11. Neighborhood Smiles Launches a Groundbreaking Cavity Prevention Program for Their Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Basel, Switzerland (PRWEB) , ... May 23, 2017 ... ... for R&D, celebrates this month its 20th anniversary, marking the occasion with a ... is sponsoring the meeting’s Welcome Reception and further extends an invitation to all ...
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... ... publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology ... the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Bacterial biofilms, surface ... molecules, can cause diverse pathologies ranging from food poisoning and catheter infections to gum ... is in the tens of billions of dollars per year, there is currently a ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... Stratevi, a ... expanded to the East Coast. It has opened an office in downtown Boston at ... are finding it increasingly more important to generate evidence on the value they provide, ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):